Administration of Angiocidin for the Treatment of Cancer

Abstract

Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

What is claimed: 
     
         1 . A method of treating a glioma in a subject, comprising administering to the subject an amount of angiocidin effective to treat the glioma. 
     
     
         2 . The method of  claim 1 , wherein angiocidin is administered in a composition comprising angiocidin and a pharmaceutically acceptable carrier. 
     
     
         3 . The method of  claim 2 , wherein angiocidin is administered to the subject in a dose of about 0.001 to 10 mg/kg body weight. 
     
     
         4 . The method of  claim 1 , further comprising administering to the subject an effective amount of fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor. 
     
     
         5 . The method of  claim 4 , wherein the angiocidin binds to the fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor to form a complex, and wherein the complex induces growth arrest of the glioma cells. 
     
     
         6 . The method of  claim 4 , wherein the angiocidin binds to the fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor to form a complex, and wherein the complex promotes healthy stem cell differentiation at or proximal to the site of the glioma. 
     
     
         7 . A method of treating breast cancer in a subject, comprising administering to the subject an amount of angiocidin effective to treat the breast cancer. 
     
     
         8 . The method of  claim 7 , wherein angiocidin is administered in a composition comprising angiocidin and a pharmaceutically acceptable carrier. 
     
     
         9 . The method of  claim 8 , wherein angiocidin is administered to the subject in a dose of about 0.001 to 10 mg/kg body weight. 
     
     
         10 . The method of  claim 7 , further comprising administering to the subject an effective amount of fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor. 
     
     
         11 . The method of  claim 10 , wherein the angiocidin binds to the fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor to form a complex, and wherein the complex induces growth arrest of the breast cancer cells. 
     
     
         12 . The method of  claim 10 , wherein the angiocidin binds to the fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor to form a complex, and wherein the complex promotes healthy stem cell differentiation at or proximal to the site of the breast cancer. 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . A method of inducing differentiation of a leukemia cell, comprising contacting the leukemia cell with an amount of angiocidin effective to induce differentiation of the leukemia cell. 
     
     
         26 . The method of  claim 25 , wherein the differentiation inhibits the tumorigenicity of the leukemia cell. 
     
     
         27 . The method of  claim 25 , wherein the differentiation induces the leukemia cell to confer a non-cancerous phenotype. 
     
     
         28 . A method for treating a tumor having a receptor for fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor in a subject, comprising administering to the subject an amount of angiocidin effective to treat the tumor expressing a receptor for fibroblast growth factor-2 or nerve growth factor. 
     
     
         29 . The method of  claim 28 , wherein angiocidin is administered in a composition comprising angiocidin and a pharmaceutically acceptable carrier. 
     
     
         30 . The method of  claim 28 , wherein angiocidin is administered to the subject in a dose of about 0.001 to 10 mg/kg body weight. 
     
     
         31 . The method of  claim 28 , wherein the tumor expressing a receptor for fibroblast growth factor-2, nerve growth factor, brain-derived neural factor, neurotropin-3, epidermal growth factor, or stem cell growth factor is glioma, breast cancer, leukemia, or melanoma.